Beta Bionics [BBNX] vs Stryker [SYK] Detailed Stock Comparison

Beta Bionics Inc.

NASDAQ
Loading...

Stryker Corporation

NYSE
Loading...

TLDR: Quick Comparison Summary

Based on 21 vital metrics comparison: Beta Bionics Inc. wins in 5 metrics, Stryker Corporation wins in 13 metrics, with 0 ties. Stryker Corporation appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric Beta Bionics Inc. Stryker Corporation Better
P/E Ratio (TTM) -6.17 39.21 Stryker Corporation
Price-to-Book Ratio 1.88 5.62 Beta Bionics Inc.
Debt-to-Equity Ratio 2.55 72.97 Beta Bionics Inc.
PEG Ratio 0.13 0.72 Beta Bionics Inc.
EV/EBITDA -4.20 19.90 Stryker Corporation
Profit Margin (TTM) -60.27% 12.92% Stryker Corporation
Operating Margin (TTM) -87.86% 27.24% Stryker Corporation
EBITDA Margin (TTM) N/A 27.24% N/A
Return on Equity -22.71% 15.08% Stryker Corporation
Return on Assets (TTM) -15.04% 7.92% Stryker Corporation
Free Cash Flow (TTM) $-56.22M $4.28B Stryker Corporation
Dividend Yield N/A 0.97% N/A
1-Year Return -29.70% -20.27% Stryker Corporation
Price-to-Sales Ratio (TTM) 4.62 5.02 Beta Bionics Inc.
Enterprise Value $316.73M $138.30B Stryker Corporation
EV/Revenue Ratio 2.87 5.51 Beta Bionics Inc.
Gross Profit Margin (TTM) 59.50% 64.54% Stryker Corporation
Revenue per Share (TTM) $3 $66 Stryker Corporation
Earnings per Share (Diluted) $-1.37 $8.40 Stryker Corporation
Beta (Stock Volatility) N/A 0.93 N/A
Short % of Float 17.13% 1.20% Stryker Corporation

Beta Bionics Inc. vs Stryker Corporation Stock Performance Analysis

Loading Price Chart...

BBNX
SYK

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Beta Bionics Inc.-2.66%7.05%21.82%7.61%-59.05%-57.44%
Stryker Corporation0.58%-3.58%1.42%-23.29%-19.39%-15.27%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Beta Bionics Inc.-29.70%-49.10%-49.10%-49.10%-49.10%-49.10%
Stryker Corporation-20.27%9.63%21.15%168.66%406.79%583.29%

Performance & Financial Health Analysis: Beta Bionics Inc. vs Stryker Corporation

MetricBBNXSYK
Market Information
Market Cap i$497.75M$126.25B
Market Cap CategorySmall capLarge cap
10 Day Avg. Volume i1,578,6181,881,406
90 Day Avg. Volume i1,188,1692,161,139
Last Close$12.45$295.00
52 Week Range$8.80 - $32.71$281.00 - $404.87
% from 52W High-61.94%-27.14%
All-Time High$32.71 (Nov 26, 2025)$406.19 (Jan 27, 2025)
% from All-Time High-61.94%-27.37%
Growth Metrics
Quarterly Revenue Growth0.57%0.11%
Quarterly Earnings Growth0.57%0.56%
Financial Health
Profit Margin (TTM) i-0.60%0.13%
Operating Margin (TTM) i-0.88%0.27%
Return on Equity (TTM) i-0.23%0.15%
Debt to Equity (MRQ) i2.5572.97
Cash & Liquidity
Book Value per Share (MRQ)$6.09$58.61
Cash per Share (MRQ)$4.48$10.71
Operating Cash Flow (TTM) i$-54,782,000$5.04B
Levered Free Cash Flow (TTM) i$-44,055,752$4.17B
Dividends
Last 12-Month Dividend Yield iN/A0.97%
Last 12-Month Dividend iN/A$3.40

Valuation & Enterprise Metrics Analysis: Beta Bionics Inc. vs Stryker Corporation

MetricBBNX (Apr 26, 2026)SYK (Apr 24, 2026)
Price Ratios
P/E Ratio (TTM) i-6.1739.21
Forward P/E i-5.6719.67
PEG Ratio i0.130.72
Price to Sales (TTM) i4.625.02
Price to Book (MRQ) i1.885.62
Market Capitalization
Market Capitalization i$497.75M$126.25B
Enterprise Value i$316.73M$138.30B
Enterprise Value Metrics
Enterprise to Revenue i2.875.51
Enterprise to EBITDA i-4.2019.90
Risk & Other Metrics
Beta iN/A0.93
Book Value per Share (MRQ) i$6.09$58.61

Financial Statements Comparison: Beta Bionics Inc. vs Stryker Corporation

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricBBNX (2025)SYK (2025)
Revenue/Sales i100.25M25.12B
Cost of Goods Sold i44.71M9.05B
COGS % of Revenue i44.6%36.0%
Gross Profit i55.54M16.07B
Gross Margin i55.4%64.0%
Research & Development i34.79M1.62B
Operating Income (EBIT) i-71.68M5.06B
Operating Margin i-71.5%20.1%
EBITDA i-56.36M6.48B
EBITDA Margin i-56.2%25.8%
Pre-Tax Income i-73.20M4.51B
Pre-Tax Income % of Revenue i-73.0%18.0%
Income Tax iN/A1.27B
Income Tax % of Revenue i0.0%5.0%
Net Income (Profit) i-73.20M3.25B
Profit Margin i-73.0%12.9%

Balance Sheet & Liquidity Metrics

MetricBBNX (2025)SYK (2025)
Cash & Equivalents i31.58M4.01B
Total Current Assets i267.91M14.76B
Total Current Assets % of Revenue i267.2%58.7%
Total Current Liabilities i30.92M7.79B
Total Current Liabilities % of Revenue i30.8%31.0%
Long-Term Debt i5.37M14.86B
Long-Term Debt % of Revenue i5.4%59.2%
Total Shareholders Equity i287.61M22.42B
Retained Earnings i-369.94M20.47B
Retained Earnings % of Revenue i-369.0%81.5%
Property, Plant & Equipment i15.87M1.79B

Cash Flow Statement Comparison

MetricBBNX (2025)SYK (2025)
Operating Cash Flow i-66.54M4.70B
Operating Cash Flow % of Revenue i-66.4%18.7%
Capital Expenditures i-5.30M-761.00M
Free Cash Flow i-56.22M4.28B
FCF Margin i-56.1%17.1%
Debt Repayment iN/A-1.40B
Common Stock Repurchase iN/AN/A

Short Interest & Institutional Ownership Analysis

MetricBBNXSYK
Shares Short i7.60M4.42M
Short Ratio i6.631.95
Short % of Float i17.13%1.20%
Shares Outstanding i44.56M382.50M
Float Shares i23.68M346.55M
% Held by Insiders i0.97%5.37%
% Held by Institutions i109.48%82.09%
% Held by Public i-10.45%12.54%

Dividend Analysis & Yield Comparison: Beta Bionics Inc. vs Stryker Corporation

MetricBBNXSYK
Last 12-Month Dividend iN/A$3.40
Last 12-Month Dividend Yield iN/A0.97%
3-Year Avg Annual Dividend iN/A$3.23
3-Year Avg Dividend Yield iN/A0.24%
3-Year Total Dividends iN/A$9.69
Ex-Dividend DateN/ADec 31, 2025